Journal Scans
Arsenic Trioxide Improves Event-Free and Over-all Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710
Arsenic Trioxide at Consolidation Improves Survival in APL
BL Powell, B Moser, W Stock, RE Gallagher, CL Willman, RM Stone, JM Rowe, S Coutre, JH Feusner, J Gregory, S Couban, FR Appelbaum, MS Tallman, RA Larson
20100712
2010 Aug 12
Blood
Arsenic Trioxide Improves Event-Free and Over-all Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710
Blood. 2010 Aug 12;[Epub Ahead of Print], BL Powell, B Moser, W Stock, RE Gallagher, CL Willman, RM Stone, JM Rowe, S Coutre, JH Feusner, J Gregory, S Couban, FR Appelbaum, MS Tallman, RA Larson
TAKE-HOME MESSAGE
Abstract
Abstract
Arsenic trioxide (As203) is a highly effective treatment for patients with relapsed acute promyelocytic leukemia (APL); its role as consolidation treatment for patients in first remission has not been defined. We randomized 481 patients (age ≥15) with untreated APL to either a standard induction regimen of tretinoin, cytarabine and daunorubicin, followed by two courses of consolidation therapy with tretinoin plus daunorubicin, or to the same induction and consolidation regimen plus two 25-day courses...
